Rafael CantÃ3n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7982912/publications.pdf

Version: 2024-02-01

499 papers 31,879 citations

80 h-index 7627 156 g-index

562 all docs 562 docs citations

times ranked

562

27166 citing authors

#	Article	IF	CITATIONS
1	Carbapenemase-producing <i>Enterobacterales</i> infections in COVID-19 patients. Infectious Diseases, 2022, 54, 36-45.	1.4	18
2	Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Journal of Clinical Microbiology, 2022, 60, JCM0027621.	1.8	56
3	Searching high and low: Call for a joint ESPID-EUCAST survey on dosage of antibacterial agents in children $\hat{a} \in \text{``Part One. Clinical Microbiology and Infection, 2022, , .}$	2.8	O
4	Imitation of \hat{l}^2 -lactam binding enables broad-spectrum metallo- \hat{l}^2 -lactamase inhibitors. Nature Chemistry, 2022, 14, 15-24.	6.6	39
5	<i>In Vitro</i> Activity of Cefepime-Taniborbactam against Carbapenemase-Producing <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0216121.	1.4	22
6	Decalogue for the selection of oral antibiotics for lower respiratory tract infections. Revista Espanola De Quimioterapia, 2022, 35, 16-29.	0.5	2
7	Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection. Journal of Clinical Microbiology, 2022, 60, jcm0224521.	1.8	18
8	Searching High and Low: Call for a Joint European Society for Paediatric Infectious Diseases-European Committee on Antimicrobial Susceptibility Testing Survey on Dosage of Antibacterial Agents in Children—Part One. Pediatric Infectious Disease Journal, 2022, 41, e182-e185.	1.1	0
9	Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy. Open Forum Infectious Diseases, 2022, 9, ofac082.	0.4	10
10	Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. Clinical Microbiology and Infection, 2022, , .	2.8	0
11	<i>In vitro</i> activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19). JAC-Antimicrobial Resistance, 2022, 4, dlac030.	0.9	2
12	CASCADE: Naked eye-detection of SARS-CoV-2 using Cas13a and gold nanoparticles. Analytica Chimica Acta, 2022, 1205, 339749.	2.6	34
13	Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection. Talanta, 2022, 243, 123393.	2.9	19
14	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. Open Forum Infectious Diseases, 2022, 9, ofab617.	0.4	3
15	Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, 2022, 12, 6454.	1.6	13
16	The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives. Microorganisms, 2022, 10, 810.	1.6	9
17	New Variants in SARS-CoV-2: What are we Learning from the Omicron Variant?. Archivos De Bronconeumologia, 2022, 58, 3-5.	0.4	2
18	Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections. BMC Microbiology, 2022, 22, 129.	1.3	8

#	Article	IF	Citations
19	Paving the way to point of care (POC) devices for SARS-CoV-2 detection. Talanta, 2022, 247, 123542.	2.9	5
20	Strain-specific predation of Bdellovibrio bacteriovorus on Pseudomonas aeruginosa with a higher range for cystic fibrosis than for bacteremia isolates. Scientific Reports, 2022, 12, .	1.6	9
21	Emergence and Persistence over Time of Carbapenemase-Producing ⟨i⟩Enterobacter⟨ i⟩ Isolates in a Spanish University Hospital in Madrid, Spain (2005–2018). Microbial Drug Resistance, 2021, 27, 895-903.	0.9	14
22	Characterization of carbapenemase-producing <i>Serratia marcescens</i> and whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016–18). Journal of Antimicrobial Chemotherapy, 2021, 76, 110-116.	1.3	16
23	Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study). International Journal of Antimicrobial Agents, 2021, 57, 106259.	1.1	11
24	Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in <i>Pseudomonas aeruginosa</i> isolates recovered from ICU patients in Spain and Portugal depicted by WGS. Journal of Antimicrobial Chemotherapy, 2021, 76, 370-379.	1.3	14
25	Fundamentos e implementación de Programas de Optimización de Diagnóstico Microbiológico. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 248-251.	0.3	4
26	Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 179-183.	0.3	9
27	Simulating the impact of non-pharmaceutical interventions limiting transmission in COVID-19 epidemics using a membrane computing model. MicroLife, 2021, 2, uqab011.	1.0	6
28	Effective antimicrobial combination <i>in vivo</i> treatment predicted with microcalorimetry screening. Journal of Antimicrobial Chemotherapy, 2021, 76, 1001-1009.	1.3	22
29	Collateral sensitivity associated with antibiotic resistance plasmids. ELife, 2021, 10, .	2.8	16
30	The impact of non-antimicrobial drug agents on the acquisition of ESBL-producing Enterobacterales in non-critical care wards in a German university hospital: an exploratory, matched case–control study. Journal of Antimicrobial Chemotherapy, 2021, 77, 229-236.	1.3	5
31	Genomic Epidemiology of SARS-CoV-2 in Madrid, Spain, during the First Wave of the Pandemic: Fast Spread and Early Dominance by D614G Variants. Microorganisms, 2021, 9, 454.	1.6	11
32	Presence of Chromosomal crpP-like Genes Is Not Always Associated with Ciprofloxacin Resistance in Pseudomonas aeruginosa Clinical Isolates Recovered in ICU Patients from Portugal and Spain. Microorganisms, 2021, 9, 388.	1.6	9
33	Activities and Perceived Risk of Transmission and Spread of SARS-CoV-2 among Specialists and Residents in a Third Level University Hospital in Spain. International Journal of Environmental Research and Public Health, 2021, 18, 2838.	1.2	5
34	Pervasive transmission of a carbapenem resistance plasmid in the gut microbiota of hospitalized patients. Nature Microbiology, 2021, 6, 606-616.	5.9	101
35	Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 1122-1129.	0.7	72
36	Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018). Revista Espanola De Quimioterapia, 2021, 34, 228-237.	0.5	8

#	Article	IF	CITATIONS
37	Fundamentals and implementation of Microbiological Diagnostic Stewardship Programs. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 248-251.	0.2	1
38	Variability of plasmid fitness effects contributes to plasmid persistence in bacterial communities. Nature Communications, 2021, 12, 2653.	5.8	96
39	Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis. Clinical Microbiology and Infection, 2021, 27, 1631-1637.	2.8	36
40	Evolution of VIM-1-Producing Klebsiella pneumoniae Isolates from a Hospital Outbreak Reveals the Genetic Bases of the Loss of the Urease-Positive Identification Character. MSystems, 2021, 6, e0024421.	1.7	5
41	Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. International Journal of Antimicrobial Agents, 2021, 57, 106345.	1.1	21
42	New variants of SARS-CoV-2. Revista Espanola De Quimioterapia, 2021, 34, 419-428.	0.5	49
43	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. Covid, 2021, 1, 20-38.	0.7	22
44	Evolutionary Pathways and Trajectories in Antibiotic Resistance. Clinical Microbiology Reviews, 2021, 34, e0005019.	5.7	71
45	Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. Journal of Global Antimicrobial Resistance, 2021, 25, 5-7.	0.9	27
46	An Immunologic Compatibility Testing Was Not Useful for Donor Selection in Fecal Microbiota Transplantation for Ulcerative Colitis. Frontiers in Immunology, 2021, 12, 683387.	2.2	6
47	Anti-biofilm activity of murepavadin against cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates. Journal of Antimicrobial Chemotherapy, 2021, 76, 2578-2585.	1.3	12
48	Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study). Mycoses, 2021, 64, 1334-1345.	1.8	12
49	Evaluation of Rapid Polymyxin Pseudomonas test in clinical Pseudomonas aeruginosa isolates with various degrees of multidrug resistance. JAC-Antimicrobial Resistance, 2021, 3, dlab104.	0.9	0
50	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2533-2541.	1.3	48
51	SARS-CoV-2 antibodies and utility of point of care testing in Health Care Workers from a spanish University Hospital in Madrid. Clinical Microbiology and Infection, 2021, 27, 1067-1068.	2.8	3
52	Emergence and Spread of B.1.1.7 Lineage in Primary Care and Clinical Impact in the Morbi-Mortality among Hospitalized Patients in Madrid, Spain. Microorganisms, 2021, 9, 1517.	1.6	12
53	<i>In vitro</i> characterization of <i>Pseudomonas aeruginosa</i> recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study). FEMS Microbiology Letters, 2021, 368, .	0.7	3
54	Evaluation of CHROMagarâ,,¢-Serratia agar, a new chromogenic medium for the detection and isolation of Serratia marcescens. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2593-2596.	1.3	1

#	Article	lF	Citations
55	Characterization of clinical Ralstonia strains and their taxonomic position. Antonie Van Leeuwenhoek, 2021, 114, 1721-1733.	0.7	14
56	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrobial Agents and Chemotherapy, 2021, 65, e0120421.	1.4	6
57	Evaluation of different phenotypic methods to detect methicillin resistance in Staphylococcus aureus isolates recovered from cystic fibrosis patients. Diagnostic Microbiology and Infectious Disease, 2021, 102, 115559.	0.8	1
58	Propensity-Score Analysis Reveals that Sex is Not a Prognostic Factor for Mortality in Intensive Care Unit-Admitted Patients with Septic Bacteremia. International Journal of Infectious Diseases, 2021, 110, 36-44.	1.5	5
59	Rapid identification from rectal swabs of the clinically most relevant carbapenemase genes from gram-negative bacteria using the BD MAX Check-Points CPO Assay. Diagnostic Microbiology and Infectious Disease, 2021, 102, 115554.	0.8	2
60	Evaluation of FASTinov Ultrarapid Flow Cytometry Antimicrobial Susceptibility Testing Directly from Positive Blood Cultures. Journal of Clinical Microbiology, 2021, 59, e0054421.	1.8	12
61	Etiology and antimicrobial susceptibility profiles of anaerobic bacteria isolated from clinical samples in a university hospital in Madrid, Spain. Anaerobe, 2021, 72, 102446.	1.0	8
62	Emergence of the New KPC-49 Variant Conferring an ESBL Phenotype with Resistance to Ceftazidime-Avibactam in the ST131-H30R1 Escherichia coli High-Risk Clone. Pathogens, 2021, 10, 67.	1.2	15
63	Lack of relationship between genotype and virulence in Candida species. Revista Iberoamericana De Micologia, 2021, 38, 9-11.	0.4	0
64	Murepavadin antimicrobial activity against and resistance development in cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates. Journal of Antimicrobial Chemotherapy, 2021, 76, 984-992.	1.3	21
65	Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota. Genes, 2021, 12, 41.	1.0	5
66	COVID-19: Impact on prescribing and antimicrobial resistance. Revista Espanola De Quimioterapia, 2021, 34, 63-68.	0.5	17
67	A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. Infectious Diseases and Therapy, 2021, 10, 2677-2699.	1.8	4
68	Implementation of contact isolation strategy for the containment of extended-spectrum \hat{l}^2 -lactamase carriers in a University Hospital positively affects the epidemiology of carbapenemase-producing Enterobacterales. Enfermedades Infecciosas Y MicrobiologÃa ClÁnica, 2021, 39, 429-435.	0.3	5
69	Implementation of contact isolation strategy for the containment of extended-spectrum β-lactamase carriers in a University Hospital positively affects the epidemiology of carbapenemase-producing Enterobacterales. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 429-435.	0.2	0
70	Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. Frontiers in Microbiology, 2021, 12, 789731.	1.5	4
71	Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria. International Journal of Molecular Sciences, 2021, 22, 13363.	1.8	2
72	Real Life Clinical Impact of Antimicrobial Stewardship Actions on the Blood Culture Workflow from a Microbiology Laboratory. Antibiotics, 2021, 10, 1511.	1.5	1

#	Article	IF	Citations
73	A 21-Year Survey of Escherichia coli from Bloodstream Infections (BSI) in a Tertiary Hospital Reveals How Community-Hospital Dynamics of B2 Phylogroup Clones Influence Local BSI Rates. MSphere, 2021, 6, e0086821.	1.3	23
74	Del CLSI al EUCAST, una transición necesaria en los laboratorios españoles. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 79-83.	0.3	11
75	Draft genome sequence of the strain 16-537536, isolated from a patient with bronchiectasis and its relationship to the Pseudomonas koreensis group of the Pseudomonas fluorescens complex. BMC Research Notes, 2020, 13, 10.	0.6	2
76	From CLSI to EUCAST, a necessary step in Spanish laboratories. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 79-83.	0.2	2
77	In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study. International Journal of Antimicrobial Agents, 2020, 55, 105887.	1.1	18
78	Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	24
79	Ultra-rapid flow cytometry assay for colistin MIC determination in Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical Microbiology and Infection, 2020, 26, 1559.e1-1559.e4.	2.8	10
80	Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 162, 102186.	1.0	8
81	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 182-187.	0.2	0
82	Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA. International Journal of Antimicrobial Agents, 2020, 56, 106082.	1.1	3
83	Surveillance studies on antimicrobial susceptibility, from international to local studies. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 147-149.	0.2	0
84	Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases. Journal of Clinical Medicine, 2020, 9, 3800.	1.0	63
85	Forty years of Tuberculous meningitis: The new face of an old enemy. International Journal of Infectious Diseases, 2020, 99, 62-68.	1.5	1
86	(p)ppGpp and Its Role in Bacterial Persistence: New Challenges. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	62
87	First national survey on the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 410-416.	0.2	3
88	WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. JAC-Antimicrobial Resistance, 2020, 2, dlaa084.	0.9	7
89	Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274). Frontiers in Microbiology, 2020, 11, 556706.	1.5	18
90	Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. Clinical Microbiology and Infection, 2020, 26, 1692-1693.	2.8	8

#	Article	IF	CITATIONS
91	Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. Current Opinion in Critical Care, 2020, 26, 433-441.	1.6	7 5
92	Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas. Frontiers in Cellular and Infection Microbiology, 2020, 10, 166.	1.8	20
93	Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine, 2020, 9, 1639.	1.0	23
94	Eikenella corrodens causing deep-seated infections. Six-year experience in a University Hospital in Madrid. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 76-78.	0.2	2
95	Emergence of ST654 Pseudomonas aeruginosa co-harbouring blaNDM-1 and blaGES-5 in novel class I integron In1884 from Bulgaria. Journal of Global Antimicrobial Resistance, 2020, 22, 672-673.	0.9	6
96	Evaluation of ultra-rapid susceptibility testing of ceftolozane-tazobactam by a flow cytometry assay directly from positive blood cultures. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1907-1914.	1.3	3
97	Isothermal microcalorimetry minimal inhibitory concentration testing in extensively drug resistant Gram-negative bacilli: a multicentre study. Clinical Microbiology and Infection, 2020, 26, 1413.e1-1413.e7.	2.8	20
98	Candidemia Candida albicans clusters have higher tendency to form biofilms than singleton genotypesâ€. Medical Mycology, 2020, 58, 887-895.	0.3	2
99	Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. Lancet Infectious Diseases, The, 2020, 20, 575-584.	4.6	43
100	Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020,	0.3	22
101	BedTAVe Summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematologia malignancies. Enfermedades Infecciosas Y Microbiologia Clinica	0.2	0
102	In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Scientific Reports, 2020, 10, 7163.	1.6	54
103	Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of <i>Enterobacterales</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> Complex. Journal of Clinical Microbiology, 2020, 58, .	1.8	16
104	Early OXA-48-Producing <i>Enterobacterales</i> Isolates Recovered in a Spanish Hospital Reveal a Complex Introduction Dominated by Sequence Type 11 (ST11) and ST405 Klebsiella pneumoniae Clones. MSphere, 2020, 5, .	1.3	15
105	Molecularly defined extraintestinal pathogenic <i>Escherichia coli</i> status predicts virulence in a murine sepsis model better than does virotype, individual virulence genes, or clonal subset among <i>E. coli</i> ST131 isolates. Virulence, 2020, 11, 327-336.	1.8	15
106	Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clinical Microbiology and Infection, 2020, 26, 1039-1043.	2.8	47
107	A publicly accessible database for Clostridioides difficile genome sequences supports tracing of transmission chains and epidemics. Microbial Genomics, 2020, 6, .	1.0	22
108	Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. Revista Espanola De Quimioterapia, 2020, 33, 466-484.	0.5	52

#	Article	IF	CITATIONS
109	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 182-187.	0.3	6
110	Eikenella corrodens causing deep-seated infections. Six-year experience in a University Hospital in Madrid. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 76-78.	0.3	3
111	Surveillance studies on antimicrobial susceptibility, from international to local studies. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 147-149.	0.3	1
112	11. Evaluation of the Bact/alert® VIRTUOâ,,¢ in Terms of Time to Detection, Performance, Workflow Efficiency and Impact on Patient Management, Compared to the BACTECâ,,¢ FX Automated Blood Culture System. Open Forum Infectious Diseases, 2020, 7, S7-S7.	0.4	0
113	Performance of CHROMID® Colistin R agar, a new chromogenic medium for screening of colistin-resistant Enterobacterales. Diagnostic Microbiology and Infectious Disease, 2019, 93, 1-4.	0.8	15
114	Evaluation of rapid colistin susceptibility directly from positive blood cultures using a flow cytometry assay. International Journal of Antimicrobial Agents, 2019, 54, 820-823.	1.1	19
115	Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis. PLoS ONE, 2019, 14, e0223326.	1.1	9
116	Intestinal co-colonization with different carbapenemase-producing Enterobacterales isolates is not a rare event in an OXA-48 endemic area. EClinicalMedicine, 2019, 15, 72-79.	3.2	27
117	Ozenoxacin: a review of preclinical and clinical efficacy. Expert Review of Anti-Infective Therapy, 2019, 17, 159-168.	2.0	30
118	Direct antimicrobial susceptibility testing from the blood culture pellet obtained for MALDI-TOF identification of Enterobacterales and Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1095-1104.	1.3	10
119	Simulating Multilevel Dynamics of Antimicrobial Resistance in a Membrane Computing Model. MBio, 2019, 10, .	1.8	24
120	Outbreak of NDM-1+CTX-M-15+DHA-1-producing Klebsiella pneumoniae high-risk clone in Spain owing to an undetectable colonised patient from Pakistan. International Journal of Antimicrobial Agents, 2019, 54, 233-239.	1.1	24
121	Microbiological profile of ozenoxacin. Future Microbiology, 2019, 14, 773-787.	1.0	9
122	Whole-genome sequencing reveals nosocomial Clostridioides difficile transmission and a previously unsuspected epidemic scenario. Scientific Reports, 2019, 9, 6959.	1.6	26
123	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	2.9	62
124	Hypermucoviscous Klebsiella pneumoniae: A challenge in community acquired infection. IDCases, 2019, 17, e00547.	0.4	37
125	Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1825-1835.	1.3	92
126	Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infectious Diseases, 2019, 6, S23-S33.	0.4	124

#	Article	IF	CITATIONS
127	Local prevalence of extended-spectrum beta-lactamase (ESBL) producing <i>Enterobacteriaceae</i> intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in <i>Klebsiella pneumoniae</i> i>: a prevalence survey in a Spanish University Hospital. BMJ Open, 2019, 9, e024879.	0.8	24
128	Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study. International Journal of Antimicrobial Agents, 2019, 53, 682-688.	1.1	37
129	Whole-genome analysis of <i>Pandoraea</i> species strains from cystic fibrosis patients. Future Microbiology, 2019, 14, 1357-1367.	1.0	2
130	Stratified reconstruction of ancestral Escherichia coli diversification. BMC Genomics, 2019, 20, 936.	1.2	23
131	PIN109 DETERMINING THE BURDEN OF CARBAPENEM-RESISTANT GRAM-NEGATIVE INFECTIONS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA). Value in Health, 2019, 22, S656-S657.	0.1	0
132	Emergence and dissemination of colistin-resistant Klebsiella pneumoniae isolates expressing OXA-48 plus CTX-M-15 in patients not previously treated with colistin in a Spanish university hospital. Diagnostic Microbiology and Infectious Disease, 2019, 93, 147-153.	0.8	6
133	Uso actual de la fosfomicina: del laboratorio a la práctica clÃnica. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 1-3.	0.3	7
134	Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIPâ€. Journal of Cystic Fibrosis, 2019, 18, 212-220.	0.3	38
135	Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing <i>Enterobacteriaceae</i> . Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	26
136	Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. Clinical Infectious Diseases, 2019, 69, 956-962.	2.9	18
137	Current approach to fosfomycin: From bench to bedside. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 1-3.	0.2	2
138	Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients. International Journal of Antimicrobial Agents, 2019, 53, 84-88.	1.1	25
139	Bronquiectasias: cuando la evidencia cientÃfica publicada no resulta suficiente. Archivos De Bronconeumologia, 2019, 55, 283-285.	0.4	10
140	Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017). Revista Espanola De Quimioterapia, 2019, 32, 145-155.	0.5	12
141	New microbiological aspects of fosfomycin. Revista Espanola De Quimioterapia, 2019, 32 Suppl 1, 8-18.	0.5	9
142	Mechanisms of action and antimicrobial activity of ceftobiprole. Revista Espanola De Quimioterapia, 2019, 32 Suppl 3, 3-10.	0.5	7
143	Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes. Revista Espanola De Quimioterapia, 2019, 32 Suppl 2, 27-31.	0.5	5
144	Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. International Journal of Antimicrobial Agents, 2018, 51, 511-515.	1.1	26

#	Article	IF	CITATIONS
145	The what, when and how in performing and interpreting microbiological diagnostic tests in skin and soft tissue infections. Current Opinion in Infectious Diseases, 2018, 31, 104-112.	1.3	14
146	Susceptibility testing and detection of \hat{l}^2 -lactam resistance mechanisms in Enterobacteriaceae: a multicentre national proficiency study. International Journal of Antimicrobial Agents, 2018, 51, 612-619.	1.1	6
147	Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults. Archivos De Bronconeumologia, 2018, 54, 79-87.	0.4	57
148	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Medicine, 2018, 44, 189-196.	3.9	101
149	Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	18
150	MIC-based dose adjustment: facts and fables. Journal of Antimicrobial Chemotherapy, 2018, 73, 564-568.	1.3	233
151	Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata. Medical Mycology, 2018, 56, 903-906.	0.3	13
152	Spanish Guidelines on Treatment of Bronchiectasis in Adults. Archivos De Bronconeumologia, 2018, 54, 88-98.	0.4	107
153	Distinct Genetic Diversity of Carbapenem-Resistant <i>Acinetobacter baumannii</i> from Colombian Hospitals. Microbial Drug Resistance, 2018, 24, 48-54.	0.9	36
154	Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplantation Reviews, 2018, 32, 36-57.	1.2	104
155	Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	21
156	Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis. Mycopathologia, 2018, 183, 7-19.	1.3	32
157	Prevalence of Aminoglycoside-Modifying Enzymes in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Producing Extended Spectrum β-Lactamases Collected in Two Multicenter Studies in Spain. Microbial Drug Resistance, 2018, 24, 367-376.	0.9	26
158	Normativa sobre la valoraci \tilde{A}^3 n y el diagn \tilde{A}^3 stico de las bronquiectasias en el adulto. Archivos De Bronconeumologia, 2018, 54, 79-87.	0.4	71
159	Normativa sobre el tratamiento de las bronquiectasias en el adulto. Archivos De Bronconeumologia, 2018, 54, 88-98.	0.4	98
160	Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of <i>Klebsiella pneumoniae </i> i>in a tertiary care hospital. Journal of Chemotherapy, 2018, 30, 115-119.	0.7	7
161	1409. Evaluation of Alternative Piperacillin–tazobactam Dosing Strategies Against ESBL-Producing Enterobacteriaceae Using a Hollowfiber Infection Model. Open Forum Infectious Diseases, 2018, 5, S434-S434.	0.4	0
162	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.3	66

#	Article	IF	CITATIONS
163	Early prosthetic endocarditis caused by Stenotrophomonas maltophilia. Médecine Et Maladies Infectieuses, 2018, 48, 543-546.	5.1	2
164	First Report of an OXA-48- and CTX-M-213-Producing Kluyvera Species Clone Recovered from Patients Admitted in a University Hospital in Madrid, Spain. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
165	Comparative <i>in vitro</i> antibacterial activity of ozenoxacin against Gram-positive clinical isolates. Future Microbiology, 2018, 13, 3-19.	1.0	19
166	Multicenter Evaluation of the Xpert Carba-R Assay for Detection of Carbapenemase Genes in Gram-Negative Isolates. Journal of Clinical Microbiology, 2018, 56, .	1.8	73
167	A review of the antibacterial activity of ozenoxacin. Future Microbiology, 2018, 13, 1-2.	1.0	6
168	MIC-based dose adjustment: facts and fablesâ€"authors' response. Journal of Antimicrobial Chemotherapy, 2018, 73, 2585-2586.	1.3	10
169	Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones. Journal of Antimicrobial Chemotherapy, 2018, 73, 3039-3043.	1.3	47
170	Fungi in Bronchiectasis: A Concise Review. International Journal of Molecular Sciences, 2018, 19, 142.	1.8	41
171	Ceftazidime Is the Key Diversification and Selection Driver of VIM-Type Carbapenemases. MBio, 2018, 9, .	1.8	18
172	Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe. Journal of Antimicrobial Chemotherapy, 2018, 73, 2973-2980.	1.3	60
173	Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. Revista Espanola De Quimioterapia, 2018, 31, 78-100.	0.5	48
174	Antimicrobial susceptibility trends and evolution of isolates with extended spectrum \hat{l}^2 -lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015). Revista Espanola De Quimioterapia, 2018, 31, 136-145.	0.5	6
175	Changes in bacterial hospital epidemiology. Revista Espanola De Quimioterapia, 2018, 31 Suppl 1, 23-26.	0.5	2
176	Characterization and rapid control of a vancomycin-resistant Enterococcus faecium (VREF) outbreak in a renal transplant unit in Spain: The environment matters. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 5-11.	0.3	6
177	MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw562.	1.3	17
178	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	4.6	367
179	Complete Genome Sequences of Isolates of Enterococcus faecium Sequence Type 117, a Globally Disseminated Multidrug-Resistant Clone. Genome Announcements, 2017, 5, .	0.8	12
180	CHROMagar mSuperCARBA performance in carbapenem-resistant Enterobacteriaceae isolates characterized at molecular level and routine surveillance rectal swab specimens. Diagnostic Microbiology and Infectious Disease, 2017, 87, 207-209.	0.8	16

#	Article	IF	CITATIONS
181	Rapid Identification of Five Classes of Carbapenem Resistance Genes Directly from Rectal Swabs by Use of the Xpert Carba-R Assay. Journal of Clinical Microbiology, 2017, 55, 2268-2275.	1.8	43
182	Characterization and rapid control of a vancomycin-resistant Enterococcus faecium (VREF) outbreak in a renal transplant unit in Spain: The environment matters. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 5-11.	0.2	0
183	Determining \hat{I}^2 -lactam exposure threshold to suppress resistance development in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2017, 72, 1421-1428.	1.3	72
184	Spread of a new Chlamydia trachomatis variant from men who have sex with men to the heterosexual population after replacement and recombination in ompA and pmpH genes. Clinical Microbiology and Infection, 2017, 23, 761-766.	2.8	7
185	Impacto económico de los métodos de diagnóstico rápido en MicrobiologÃa ClÃnica: precio de la prueba o impacto clÃnico global. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 659-666.	0.3	6
186	Individual Patterns of Complexity in Cystic Fibrosis Lung Microbiota, Including Predator Bacteria, over a 1-Year Period. MBio, 2017, 8, .	1.8	38
187	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	3.1	788
188	Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study. International Journal of Antimicrobial Agents, 2017, 50, 334-341.	1.1	20
189	Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone. Scientific Reports, 2017, 7, 5555.	1.6	117
190	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	1.1	8
191	Elucidating constraints for differentiation of major human Klebsiella pneumoniae clones using MALDI-TOF MS. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 379-386.	1.3	18
192	Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infectious Diseases, The, 2017, 17, 153-163.	4.6	522
193	Etest $\hat{A}^{@}$ versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus : results from PREMIUM, a European multicentre study. Journal of Antimicrobial Chemotherapy, 2017, 72, 431-436.	1.3	17
194	Long-term clonal dynamics of (i>Enterococcus faecium (i>strains causing bloodstream infections (1995–2015) in Spain. Journal of Antimicrobial Chemotherapy, 2017, 72, 48-55.	1.3	51
195	First description of late recurrence of catheter-associated bacteraemia due to Cellulosimicrobium cellulans. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 131-133.	0.3	5
196	The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clinical Microbiology and Infection, 2017, 23, 2-22.	2.8	428
197	In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	26
198	Economic impact of rapid diagnostic methods in Clinical Microbiology: Price of the test or overall clinical impact. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 659-666.	0.2	0

#	Article	IF	Citations
199	P782 A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitis. Journal of Crohn's and Colitis, 2017, 11, S480-S481.	0.6	7
200	Insights into a Novel blaKPC-2-Encoding IncP-6 Plasmid Reveal Carbapenem-Resistance Circulation in Several Enterobacteriaceae Species from Wastewater and a Hospital Source in Spain. Frontiers in Microbiology, 2017, 8, 1143.	1.5	50
201	Potential Impact of Flow Cytometry Antimicrobial Susceptibility Testing on the Clinical Management of Gram-Negative Bacteremia Using the FASTinov® Kit. Frontiers in Microbiology, 2017, 8, 2455.	1.5	23
202	Virulence genes and subclone status as markers of experimental virulence in a murine sepsis model among Escherichia coli sequence type 131 clinical isolates from Spain. PLoS ONE, 2017, 12, e0188838.	1.1	7
203	Antibiotic prescription patterns in Spanish cystic fibrosis patients: results from a national multicenter study. Farmacia Hospitalaria, 2017, 41, 391-400.	0.6	1
204	Evolutionary Biology of Drug Resistance. , 2017, , 9-36.		2
205	Fluconazole-containing agar Sabouraud dextrose plates are not useful when screening for susceptibility in Candida albicans. Revista Espanola De Quimioterapia, 2017, 30, 127-130.	0.5	0
206	Shortcomings of the Commercial MALDI-TOF MS Database and Use of MLSA as an Arbiter in the Identification of Nocardia Species. Frontiers in Microbiology, 2016, 7, 542.	1.5	18
207	Prevalence of Escherichia coli Virulence Genes in Patients with Diarrhea and a Subpopulation of Healthy Volunteers in Madrid, Spain. Frontiers in Microbiology, 2016, 7, 641.	1.5	37
208	A Flow Cytometric and Computational Approaches to Carbapenems Affinity to the Different Types of Carbapenemases. Frontiers in Microbiology, 2016, 7, 1259.	1.5	5
209	Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2016, 84, 334-336.	0.8	4
210	Rapid Flow Cytometry Test for Identification of Different Carbapenemases in Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 3824-3826.	1.4	12
211	Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 2912-2922.	1.4	25
212	Multisite Evaluation of Cepheid Xpert Carba-R Assay for Detection of Carbapenemase-Producing Organisms in Rectal Swabs. Journal of Clinical Microbiology, 2016, 54, 1814-1819.	1.8	109
213	Gut eradication of VIM-1 producing ST9 Klebsiella oxytoca after fecal microbiota transplantation for diarrhea caused by a Clostridium difficile hypervirulent RO27 strain. Diagnostic Microbiology and Infectious Disease, 2016, 86, 470-471.	0.8	26
214	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	1.4	89
215	CTX-M-15- <i>H</i> 30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producing <i>Escherichia coli</i> bacteraemia of urinary origin in Spain. Journal of Antimicrobial Chemotherapy, 2016, 71, 2125-2130.	1.3	46
216	Is a New Standard Needed for Diffusion Methods for In VitroSusceptibility Testing of Fosfomycin against Pseudomonas aeruginosa?. Antimicrobial Agents and Chemotherapy, 2016, 60, 1158-1161.	1.4	8

#	Article	IF	CITATIONS
217	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	1.3	41
218	<i>Escherichia coli</i> : an old friend with new tidings. FEMS Microbiology Reviews, 2016, 40, 437-463.	3.9	225
219	Emergence of <i>cfr</i> -Mediated Linezolid Resistance in a Methicillin-Resistant Staphylococcus aureus Epidemic Clone Isolated from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 1878-1882.	1.4	25
220	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. Journal of Antimicrobial Chemotherapy, 2016, 71, 521-530.	1.3	21
221	Detection of Carbapenemase Production in a Collection of Enterobacteriaceae with Characterized Resistance Mechanisms from Clinical and Environmental Origins by Use of Both Carba NP and Blue-Carba Tests. Journal of Clinical Microbiology, 2016, 54, 464-466.	1.8	19
222	Comparison of different methods for identification of species of the genus Raoultella: report of 11 cases of Raoultella causing bacteraemia and literature review. Clinical Microbiology and Infection, 2016, 22, 252-257.	2.8	36
223	A single-day point-prevalence study of faecal carriers in long-term care hospitals in Madrid (Spain) depicts a complex clonal and polyclonal dissemination of carbapenemase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2016, 71, 348-352.	1.3	41
224	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. Journal of Infection, 2016, 72, 152-160.	1.7	73
225	The rise of ampicillin-resistant Enterococcus faecium high-risk clones as a frequent intestinal colonizer in oncohaematological neutropenic patients on levofloxacin prophylaxis: a risk for bacteraemia?. Clinical Microbiology and Infection, 2016, 22, 59.e1-59.e8.	2.8	11
226	Bronchopulmonary infection–colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. Journal of Cystic Fibrosis, 2016, 15, 357-365.	0.3	16
227	New Insights into the Enterococcus faecium and Streptococcus gallolyticus subsp. gallolyticus Host Interaction Mechanisms. PLoS ONE, 2016, 11, e0159159.	1.1	6
228	Evaluation of the eazyplex \hat{A}^{\circledast} SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals. Journal of Antimicrobial Chemotherapy, 2015, 70, 1047-1050.	1.3	62
229	Detection of virulenceâ€associated genes characteristic of intestinal <i>Escherichia coli</i> pathotypes, including the enterohemorrhagic/enteroaggregative O104:H4, in bovines from Germany and Spain. Microbiology and Immunology, 2015, 59, 433-442.	0.7	15
230	Population Biology of Intestinal Enterococcus Isolates from Hospitalized and Nonhospitalized Individuals in Different Age Groups. Applied and Environmental Microbiology, 2015, 81, 1820-1831.	1.4	75
231	Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quÃstica. Archivos De Bronconeumologia, 2015, 51, 140-150.	0.4	35
232	Antibiotic-Resistant Klebsiella pneumoniae and Escherichia coli High-Risk Clones and an IncFII $\langle \text{sub} \rangle \text{k} \langle \text{sub} \rangle$ Mosaic Plasmid Hosting Tn $\langle \text{i} \rangle 1 \langle \text{i} \rangle \langle \text{sub} \rangle \rangle$ in Isolates from 1990 to 2004. Antimicrobial Agents and Chemotherapy, 2015, 59, 2904-2908.	1.4	9
233	Dissemination of High-Risk Clones of Extensively Drug-Resistant Pseudomonas aeruginosa in Colombia. Antimicrobial Agents and Chemotherapy, 2015, 59, 2421-2425.	1.4	58
234	In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response. Mucosal Immunology, 2015, 8, 362-371.	2.7	18

#	Article	IF	CITATIONS
235	Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients. Archivos De Bronconeumologia, 2015, 51, 140-150.	0.4	17
236	Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations. Antimicrobial Agents and Chemotherapy, 2015, 59, 6039-6045.	1.4	33
237	Sequencing of plasmids pAMBL1 and pAMBL2 from i>Pseudomonas aeruginosa /i>reveals a <i> bla < /i > < sub > VIM-1 < / sub > amplification causing high-level carbapenem resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 3000-3003.</i>	1.3	35
238	Reviving old antibiotics. Journal of Antimicrobial Chemotherapy, 2015, 70, 2177-2181.	1.3	79
239	Preterm infant gut colonization in the neonatal ICU and complete restoration 2 years later. Clinical Microbiology and Infection, 2015, 21, 936.e1-936.e10.	2.8	57
240	Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coliisolates with characterized resistance phenotypes. Journal of Antimicrobial Chemotherapy, 2015, 70, 2306-2310.	1.3	14
241	Clusters of patients with candidaemia due to genotypes of Candida albicans and Candida parapsilosis: differences in frequency between hospitals. Clinical Microbiology and Infection, 2015, 21, 677-683.	2.8	15
242	High Prevalence of Co-Infections by Invasive and Non-Invasive Chlamydia trachomatis Genotypes during the Lymphogranuloma Venereum Outbreak in Spain. PLoS ONE, 2015, 10, e0126145.	1.1	13
243	In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. International Journal of Antimicrobial Agents, 2015, 45, 641-646.	1.1	42
244	Streptococcus gallolyticus subsp. gallolyticus from Human and Animal Origins: Genetic Diversity, Antimicrobial Susceptibility, and Characterization of a Vancomycin-Resistant Calf Isolate Carrying a <i>vanA</i> -Tn <i>1546</i> -Like Element. Antimicrobial Agents and Chemotherapy, 2015, 59, 2006-2015.	1.4	15
245	Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 5903-5908.	1.4	54
246	In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. International Journal of Antimicrobial Agents, 2015, 46, 502-510.	1.1	50
247	Response to "In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response†Mucosal Immunology, 2015, 8, 697-698.	2.7	8
248	Public health evolutionary biology of antimicrobial resistance: priorities for intervention. Evolutionary Applications, 2015, 8, 223-239.	1.5	47
249	Molecular Characterization and Genetic Diversity of ESBL-Producing <i>Escherichia coli</i> Colonizing the Migratory Franklin's Gulls (<i>Leucophaeus pipixcan</i>) in Antofagasta, North of Chile. Microbial Drug Resistance, 2015, 21, 111-116.	0.9	48
250	CTX-M-15-non-ST131 Escherichia coli isolates are mainly responsible of faecal carriage with ESBL-producing Enterobacteriaceae in travellers, immigrants and those visiting friends and relatives. Clinical Microbiology and Infection, 2015, 21, 252.e1-252.e4.	2.8	27
251	European survey on principles of prudent antibiotic prescribing teaching in undergraduate students. Clinical Microbiology and Infection, 2015, 21, 354-361.	2.8	44
252	In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci. Journal of Antimicrobial Chemotherapy, 2015, 70, 57-61.	1.3	12

#	Article	IF	Citations
253	Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. Eurosurveillance, 2015, 20, .	3.9	36
254	High Clonal Diversity in a Non-Outbreak Situation of Clinical ESBL-Producing <i>Klebsiella pneumoniae</i> Isolates in the First National Surveillance Program in Cuba. Microbial Drug Resistance, 2014, 20, 45-51.	0.9	16
255	Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices. BMC Microbiology, 2014, 14, 335.	1.3	8
256	Breakpoints for carbapenemase-producing Enterobacteriaceae: Is the problem solved?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 33-40.	0.3	14
257	Staphylococcus aureusCarryingmecC Gene in Animals and Urban Wastewater, Spain. Emerging Infectious Diseases, 2014, 20, 899-901.	2.0	46
258	Detection of Resistance to Beta-Lactamase Inhibitors in Strains with CTX-M Beta-Lactamases: a Multicenter External Proficiency Study Using a Well-Defined Collection of Escherichia coli Strains. Journal of Clinical Microbiology, 2014, 52, 122-129.	1.8	18
259	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. Journal of Hepatology, 2014, 60, 1310-1324.	1.8	685
260	Pandemic Influenza A (H1N1) in Non-vaccinated, Pregnant Women in Spain (2009–2010). Maternal and Child Health Journal, 2014, 18, 1454-1461.	0.7	3
261	Rapid Detection of \hat{l}^2 -Lactamase-Hydrolyzing Extended-Spectrum Cephalosporins in Enterobacteriaceae by Use of the New Chromogenic \hat{l}^2 Lacta Test. Journal of Clinical Microbiology, 2014, 52, 1741-1744.	1.8	24
262	Clinical and epidemiological characterization of a lymphogranuloma venereum outbreak in Madrid, Spain: co-circulation of two variants. Clinical Microbiology and Infection, 2014, 20, 219-225.	2.8	55
263	Individual variability in fingerâ€ŧoâ€finger transmission efficiency of Enterococcus faecium clones. MicrobiologyOpen, 2014, 3, 128-132.	1.2	9
264	Evaluation of a Loop-Mediated Isothermal Amplification-Based Methodology To Detect Carbapenemase Carriage in Acinetobacter Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 7538-7540.	1.4	24
265	First Report of Macrolide Resistance in a Mycoplasma pneumoniae Isolate Causing Community-Acquired Pneumonia in Spain. Antimicrobial Agents and Chemotherapy, 2014, 58, 1265-1266.	1.4	18
266	MALDI-TOF mass spectrometry as a tool for the discrimination of high-risk Escherichia coli clones from phylogenetic groups B2 (ST131) and D (ST69, ST405, ST393). European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1391-1399.	1.3	48
267	Emergence and Long-Lasting Persistence of Linezolid-ResistantEnterococcus faecium-ST117 in an Oncohematologic Patient After a Nine-Day Course of Linezolid. Microbial Drug Resistance, 2014, 20, 17-21.	0.9	12
268	Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: A double blind prospective study. Journal of Cystic Fibrosis, 2014, 13, 716-722.	0.3	107
269	Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values. Diagnostic Microbiology and Infectious Disease, 2014, 78, 263-267.	0.8	38
270	Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opinion on Therapeutic Targets, 2014, 18, 851-861.	1.5	22

#	Article	IF	Citations
271	Epidemiology and Evolution of Beta-Lactamases. , 2014, , 249-270.		2
272	Recombination Blurs Phylogenetic Groups Routine Assignment in Escherichia coli: Setting the Record Straight. PLoS ONE, 2014, 9, e105395.	1.1	27
273	Risk factors and effectiveness of preventive measures against influenza in the community. Influenza and Other Respiratory Viruses, 2013, 7, 177-183.	1.5	25
274	Detection of Colonization by Carbapenemase-Producing Gram-Negative Bacilli in Patients by Use of the Xpert MDRO Assay. Journal of Clinical Microbiology, 2013, 51, 3780-3787.	1.8	80
275	Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 3-11.	0.3	68
276	Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010. International Journal of Antimicrobial Agents, 2013, 41, 224-228.	1.1	31
277	A novel flow cytometric assay for rapid detection of extended-spectrum beta-lactamases. Clinical Microbiology and Infection, 2013, 19, E8-E15.	2.8	45
278	Non-diphtheriae Corynebacterium species: an emerging respiratory pathogen. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 769-772.	1.3	66
279	Antibiotics as selectors and accelerators of diversity in the mechanisms of resistance: from the resistome to genetic plasticity in the \hat{I}^2 -lactamases world. Frontiers in Microbiology, 2013, 4, 9.	1.5	54
280	Inhaled antibiotics for the treatment of chronic bronchopulmonary <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opinion on Pharmacotherapy, 2013, 14, 1135-1149.	0.9	46
281	EUCAST expert rules in antimicrobial susceptibility testing. Clinical Microbiology and Infection, 2013, 19, 141-160.	2.8	527
282	In VitroActivity of Fosfomycin against a Collection of Clinical Pseudomonas aeruginosa Isolates from 16 Spanish Hospitals: Establishing the Validity of Standard Broth Microdilution as Susceptibility Testing Method. Antimicrobial Agents and Chemotherapy, 2013, 57, 5701-5703.	1.4	33
283	Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and Â-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 2013, 68, 164-167.	1.3	35
284	Multiclonal dispersal of KPC genes following the emergence of non-ST258 KPC-producing Klebsiella pneumoniae clones in Madrid, Spain. Journal of Antimicrobial Chemotherapy, 2013, 68, 2487-2492.	1.3	48
285	<i>In Vitro</i> Activity of Ozenoxacin against Quinolone-Susceptible and Quinolone-Resistant Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy, 2013, 57, 6389-6392.	1.4	36
286	Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed Influenza. Clinical Infectious Diseases, 2013, 57, 167-175.	2.9	112
287	Population Structure and Antimicrobial Susceptibility of Both Nonpersistent and Persistent Pseudomonas aeruginosa Isolates Recovered from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2013, 51, 2761-2765.	1.8	30
288	International Multicenter Evaluation of the DiversiLab Bacterial Typing System for Escherichia coli and Klebsiella spp Journal of Clinical Microbiology, 2013, 51, 3944-3949.	1.8	9

#	Article	IF	Citations
289	Assessment of Virulence Factors Characteristic of Human Escherichia coli Pathotypes and Antimicrobial Resistance in O157:H7 and Non-O157:H7 Isolates from Livestock in Spain. Applied and Environmental Microbiology, 2013, 79, 4170-4172.	1.4	25
290	Melioidosis in Traveler from Africa to Spain. Emerging Infectious Diseases, 2013, 19, 1656-1659.	2.0	26
291	Normal Mutation Rate Variants Arise in a Mutator (Mut S) Escherichia coli Population. PLoS ONE, 2013, 8, e72963.	1.1	37
292	Commensal Enterobacteriaceae as reservoirs of extended-spectrum beta-lactamases, integrons, and sul genes in Portugal. Frontiers in Microbiology, 2013, 4, 80.	1.5	29
293	Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Eurosurveillance, 2013, 18, .	3.9	198
294	Contribution of IncFII and Broad-Host IncA/C and IncN Plasmids to the Local Expansion and Diversification of Phylogroup B2 Escherichia coli ST131 Clones Carrying <i>bla</i> _{CTX-M-15} and <i>qnrS1</i> Genes. Antimicrobial Agents and Chemotherapy, 2012, 56, 2763-2766.	1.4	27
295	Clinical and Microbiological Features of a Cystic Fibrosis Patient Chronically Colonized with Pandoraea sputorum Identified by Combining 16S rRNA Sequencing and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. Journal of Clinical Microbiology, 2012, 50, 1096-1098.	1.8	26
296	Reply to "Expansion of Clonal Complex 258 KPC-2-Producing Klebsiella pneumoniae in Latin American Hospitals: Report of the SENTRY Antimicrobial Surveillance Program― Antimicrobial Agents and Chemotherapy, 2012, 56, 1670-1671.	1.4	5
297	Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. Journal of Antimicrobial Chemotherapy, 2012, 67, 1739-1745.	1.3	19
298	Reply to "Clonal Complex 258, the Most Frequently Found Multilocus Sequence Type Complex in KPC-2-Producing Klebsiella pneumoniae Isolated in Brazilian Hospitals― Antimicrobial Agents and Chemotherapy, 2012, 56, 4565-4565.	1.4	1
299	Emergence of a <i>mutL</i> Mutation Causing Multilocus Sequence Typing–Pulsed-Field Gel Electrophoresis Discrepancy among Pseudomonas aeruginosa Isolates from a Cystic Fibrosis Patient. Journal of Clinical Microbiology, 2012, 50, 1777-1778.	1.8	21
300	CTX-M Enzymes: Origin and Diffusion. Frontiers in Microbiology, 2012, 3, 110.	1.5	707
301	Assessment of the Phoenixâ,,¢ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanisms. Clinical Microbiology and Infection, 2012, 18, E452-E458.	2.8	15
302	Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clinical Microbiology and Infection, 2012, 18, 253-259.	2.8	45
303	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clinical Microbiology and Infection, 2012, 18, E37-E45.	2.8	232
304	Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clinical Microbiology and Infection, 2012, 18, 413-431.	2.8	727
305	Emergence of antibiotic resistance: need for a new paradigm. Clinical Microbiology and Infection, 2012, 18, 615-616.	2.8	47
306	MALDI-TOF MS improves routine identification of non-fermenting Gram negative isolates from cystic fibrosis patients. Journal of Cystic Fibrosis, 2012, 11, 59-62.	0.3	87

#	Article	IF	CITATIONS
307	Fecal Carriage of Carbapenemase-Producing Enterobacteriaceae: a Hidden Reservoir in Hospitalized and Nonhospitalized Patients. Journal of Clinical Microbiology, 2012, 50, 1558-1563.	1.8	68
308	In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. International Journal of Antimicrobial Agents, 2012, 40, 173-176.	1.1	34
309	Sociodemographic Factors and Clinical Conditions Associated to Hospitalization in Influenza A (H1N1) 2009 Virus Infected Patients in Spain, 2009–2010. PLoS ONE, 2012, 7, e33139.	1.1	20
310	High-density fecal Enterococcus faecium colonization in hospitalized patients is associated with the presence of the polyclonal subcluster CC17. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 519-522.	1.3	22
311	Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization. Preventive Medicine, 2012, 54, 434-439.	1.6	52
312	Multi-Locus Variable Number of Tandem Repeat Analysis for Rapid and Accurate Typing of Virulent Multidrug Resistant Escherichia coli Clones. PLoS ONE, 2012, 7, e41232.	1.1	32
313	Emerging resistance in Gram-negative pathogens and implications for clinical practice. Future Microbiology, $2011, 6, 19-22$.	1.0	6
314	Co-resistance: an opportunity for the bacteria and resistance genes. Current Opinion in Pharmacology, 2011, 11, 477-485.	1.7	162
315	Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resistance Updates, 2011, 14, 107-117.	6.5	175
316	Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients. Clinical Microbiology and Infection, 2011, 17, 704-711.	2.8	10
317	Molecular analysis of community-acquired methicillin-susceptible and resistant Staphylococcus aureus isolates recovered from bacteraemic and osteomyelitis infections in children from Tunisia. Clinical Microbiology and Infection, 2011, 17, 1020-1026.	2.8	42
318	Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiology Reviews, 2011, 35, 977-991.	3.9	256
319	<i>In Vitro</i> Selection of Variants Resistant to \hat{I}^2 -Lactams plus \hat{I}^2 -Lactamase Inhibitors in CTX-M \hat{I}^2 -Lactamases: Predicting the <i>In Vivo</i> Scenario?. Antimicrobial Agents and Chemotherapy, 2011, 55, 4530-4536.	1.4	39
320	Comparative activity of carbapenem testing: the COMPACT study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1070-1078.	1.3	37
321	Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. Journal of Antimicrobial Chemotherapy, 2011, 66, 151-159.	1.3	24
322	Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Clinical Strains in 16 Spanish Hospitals. Journal of Clinical Microbiology, 2011, 49, 2905-2910.	1.8	76
323	First Characterization of CTX-M-15-Producing Escherichia coli ST131 and ST405 Clones Causing Community-Onset Infections in South America. Journal of Clinical Microbiology, 2011, 49, 1993-1996.	1.8	41
324	Association of Composite IS <i>26-sul3</i> Elements with Highly Transmissible Incl1 Plasmids in Extended-Spectrum-β-Lactamase-Producing Escherichia coli Clones from Humans. Antimicrobial Agents and Chemotherapy, 2011, 55, 2451-2457.	1.4	47

#	Article	IF	CITATIONS
325	Reidentification of Streptococcus bovis Isolates Causing Bacteremia According to the New Taxonomy Criteria: Still an Issue?. Journal of Clinical Microbiology, 2011, 49, 3228-3233.	1.8	78
326	A potential role for daptomycin in enterococcal infections: what is the evidence?—authors' response. Journal of Antimicrobial Chemotherapy, 2011, 66, 1196-1197.	1.3	0
327	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial Chemotherapy, 2011, 66, 2022-2027.	1.3	132
328	Dissemination of <i>bla</i> _{KPC-2} by the Spread of Klebsiella pneumoniae Clonal Complex 258 Clones (ST258, ST11, ST437) and Plasmids (IncFII, IncN, IncL/M) among Enterobacteriaceae Species in Brazil. Antimicrobial Agents and Chemotherapy, 2011, 55, 3579-3583.	1.4	168
329	Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum \hat{l}^2 -lactamases in the SMART study in Spain (2002-2010). Revista Espanola De Quimioterapia, 2011, 24, 223-32.	0.5	20
330	Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clinical Microbiology and Infection, 2010, 16, 112-122.	2.8	287
331	Public health microbiology, a challenge for Europe. Clinical Microbiology and Infection, 2010, 16, 123-125.	2.8	11
332	Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clinical Microbiology and Infection, 2010, 16, 1482-1487.	2.8	31
333	Cystic fibrosis: deciphering the complexity. Clinical Microbiology and Infection, 2010, 16, 793-797.	2.8	9
334	Population Analysis and Epidemiological Features of Inhibitor-Resistant-TEM- \hat{l}^2 -Lactamase-Producing <i>Escherichia coli</i> Isolates from both Community and Hospital Settings in Madrid, Spain. Journal of Clinical Microbiology, 2010, 48, 2368-2372.	1.8	21
335	Dispersal of Carbapenemase <i>bla</i> _{VIM-1} Gene Associated with Different Tn <i>402</i> Variants, Mercury Transposons, and Conjugative Plasmids in <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> Antimicrobial Agents and Chemotherapy, 2010, 54, 320-327.	1.4	84
336	Global Spread of the <i>hyl</i> _{Efm} Colonization-Virulence Gene in Megaplasmids of the <i>Enterococcus faecium</i> CC17 Polyclonal Subcluster. Antimicrobial Agents and Chemotherapy, 2010, 54, 2660-2665.	1.4	67
337	Carbapenem Heteroresistance in VIM-1-Producing <i>Klebsiella pneumoniae</i> Isolates Belonging to the Same Clone: Consequences for Routine Susceptibility Testing. Journal of Clinical Microbiology, 2010, 48, 4089-4093.	1.8	56
338	Multicenter Study Evaluating the Role of Enterococci in Secondary Bacterial Peritonitis. Journal of Clinical Microbiology, 2010, 48, 456-459.	1.8	34
339	Persistent isolation of Salmonella Concord harbouring CTX-M-15, SHV-12 and QnrA1 in an asymptomatic adopted Ethiopian child in Spain also colonized with CTX-M-14- and QnrB-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2010, 65, 1545-1546.	1.3	9
340	A potential role for daptomycin in enterococcal infections: what is the evidence?. Journal of Antimicrobial Chemotherapy, 2010, 65, 1126-1136.	1.3	81
341	Polymorphic Mutation Frequencies of Clinical and Environmental <i>Stenotrophomonas maltophilia</i> Populations. Applied and Environmental Microbiology, 2010, 76, 1746-1758.	1.4	55
342	International Spread and Persistence of TEM-24 Is Caused by the Confluence of Highly Penetrating <i>Enterobacteriaceae</i> Clones and an IncA/C ₂ Plasmid Containing Tn <i>1696</i> ::Tn <i>1</i> and IS <i>5075</i> -Tn <i>21</i> Antimicrobial Agents and Chemotherapy, 2010, 54, 825-834.	1.4	41

#	Article	IF	CITATIONS
343	Evolutionary Trajectories of Beta-Lactamase CTX-M-1 Cluster Enzymes: Predicting Antibiotic Resistance. PLoS Pathogens, 2010, 6, e1000735.	2.1	100
344	Emergence of blaKPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. Journal of Antimicrobial Chemotherapy, 2010, 65, 1608-1614.	1.3	74
345	Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization. Journal of Microbiological Methods, 2010, 82, 98-101.	0.7	27
346	Assessment of prevalence and changing epidemiology of extended-spectrum β-lactamase–producing Enterobacteriaceae fecal carriers using a chromogenic medium. Diagnostic Microbiology and Infectious Disease, 2010, 67, 376-379.	0.8	32
347	Prudent use of antimicrobials: Have we done the best we can? The SEIMC and REIPI statement. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 485-486.	0.3	6
348	Incidence and Antimicrobial Susceptibility of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrobial Agents and Chemotherapy, 2010, 54, 3043-3046.	1.4	77
349	Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Eurosurveillance, 2010, 15 , .	3.9	212
350	Redefining extended-spectrum Â-lactamases: balancing science and clinical needauthors' response. Journal of Antimicrobial Chemotherapy, 2009, 64, 213-215.	1.3	8
351	Leakage into Portuguese aquatic environments of extended-spectrum-Â-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2009, 63, 616-618.	1.3	26
352	High clonal diversity in erythromycin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain (2000-07). Journal of Antimicrobial Chemotherapy, 2009, 64, 1165-1169.	1.3	6
353	Spread of <i>bla</i> _{CTX-M-14} Is Driven Mainly by IncK Plasmids Disseminated among <i>Escherichia coli</i> Phylogroups A, B1, and D in Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 5204-5212.	1.4	112
354	Escherichia coli producing SHV-type extended-spectrum Â-lactamase is a significant cause of community-acquired infection. Journal of Antimicrobial Chemotherapy, 2009, 63, 781-784.	1.3	24
355	Longer Intestinal Persistence of Enterococcus faecalis Compared to Enterococcus faecium Clones in Intensive-Care-Unit Patients. Journal of Clinical Microbiology, 2009, 47, 345-351.	1.8	13
356	Unorthodox longâ€ŧerm aerosolized ampicillin use for methicillinâ€susceptible <i>Staphylococcus aureus</i> lung infection in a cystic fibrosis patient. Pediatric Pulmonology, 2009, 44, 512-515.	1.0	10
357	Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. Clinical Microbiology and Infection, 2009, 15, 20-25.	2.8	189
358	Extended-spectrum \hat{I}^2 -lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International Journal of Antimicrobial Agents, 2009, 34, 173-176.	1.1	164
359	Evolutionary Biology of Drug Resistance. , 2009, , 9-32.		4
360	Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. Clinical Microbiology and Infection, 2009, 16, no-no.	2.8	16

#	Article	IF	CITATIONS
361	Antibiotics and antibiotic resistance in water environments. Current Opinion in Biotechnology, 2008, 19, 260-265.	3.3	1,608
362	IRT and CMT \hat{l}^2 -lactamases and inhibitor resistance. Clinical Microbiology and Infection, 2008, 14, 53-62.	2.8	92
363	Prevalence and spread of extended-spectrum \hat{l}^2 -lactamase-producing Enterobacteriaceae in Europe. Clinical Microbiology and Infection, 2008, 14, 144-153.	2.8	495
364	Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clinical Microbiology and Infection, 2008, 14, 307-314.	2.8	36
365	Diagnosis and Treatment of Bronchiectasis. Archivos De Bronconeumologia, 2008, 44, 629-640.	0.4	37
366	Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase–producing Klebsiella pneumoniae epidemic clone. Diagnostic Microbiology and Infectious Disease, 2008, 60, 319-322.	0.8	49
367	Commentary on manuscript: Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagnostic Microbiology and Infectious Disease, 2008, 61, 360-361.	0.8	4
368	High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. Journal of Antimicrobial Chemotherapy, 2008, 62, 961-967.	1.3	56
369	Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2008, 63, 60-66.	1.3	66
370	Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli. Archives of Internal Medicine, 2008, 168, 1897.	4.3	333
371	Polyclonal Population Structure of <i>Streptococcus pneumoniae</i> Isolates in Spain Carrying <i>mef</i> and <i>mef</i> plus <i>erm</i> (B). Antimicrobial Agents and Chemotherapy, 2008, 52, 1964-1969.	1.4	16
372	Mutational Events in Cefotaximase Extended-Spectrum \hat{l}^2 -Lactamases of the CTX-M-1 Cluster Involved in Ceftazidime Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 2377-2382.	1.4	40
373	Redefining extended-spectrum \hat{A} -lactamases: balancing science and clinical need. Journal of Antimicrobial Chemotherapy, 2008, 63, 1-4.	1.3	92
374	Antibiotic resistance integrons and extended-spectrum Â-lactamases among Enterobacteriaceae isolates recovered from chickens and swine in Portugal. Journal of Antimicrobial Chemotherapy, 2008, 62, 296-302.	1.3	147
375	High Rate of Intestinal Colonization with Extended-Spectrum-Î ² -Lactamase-Producing Organisms in Household Contacts of Infected Community Patients. Journal of Clinical Microbiology, 2008, 46, 2796-2799.	1.8	157
376	Dissemination of Clonally Related <i>Escherichia coli </i> Strains Expressing Extended - Spectrum β-Lactamase CTX-M-15. Emerging Infectious Diseases, 2008, 14, 195-200.	2.0	672
377	Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance, 2008, 13, .	3.9	526
378	Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance, 2008, 13, .	3.9	219

#	Article	IF	CITATIONS
379	Complex molecular epidemiology of extended-spectrum -lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid. Journal of Antimicrobial Chemotherapy, 2007, 61, 64-72.	1.3	50
380	Emergence and Dissemination of Enterobacteriaceae Isolates Producing CTX-M-1-Like Enzymes in Spain Are Associated with IncFII (CTX-M-15) and Broad-Host-Range (CTX-M-1, -3, and -32) Plasmids. Antimicrobial Agents and Chemotherapy, 2007, 51, 796-799.	1.4	110
381	Preservation of Integron Types among Enterobacteriaceae Producing Extended-Spectrum \hat{I}^2 -Lactamases in a Spanish Hospital over a 15-Year Period (1988 to 2003). Antimicrobial Agents and Chemotherapy, 2007, 51, 2201-2204.	1.4	42
382	Learning from mistakes: Taq polymerase contaminated with \hat{l}^2 -lactamase sequences results in false emergence of Streptococcus pneumoniae containing TEM. Journal of Antimicrobial Chemotherapy, 2007, 60, 702-703.	1.3	21
383	Complex Clonal and Plasmid Epidemiology in the First Outbreak of Enterobacteriaceae Infection Involving VIM-1 Metallo-Â-Lactamase in Spain: Toward Endemicity?. Clinical Infectious Diseases, 2007, 45, 1171-1178.	2.9	109
384	High diversity of extended-spectrum Â-lactamases among clinical isolates of Enterobacteriaceae from Portugal. Journal of Antimicrobial Chemotherapy, 2007, 60, 1370-1374.	1.3	53
385	P1034 International dissemination of extended-spectrum \hat{l}^2 -lactamase TEM-24 among Enterobacteriaceae species is caused by spread of both epidemic IncA/C2 plasmid and strains. International Journal of Antimicrobial Agents, 2007, 29, S277.	1.1	2
386	Metallo- \hat{l}^2 -lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	1.1	134
387	Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004). International Journal of Antimicrobial Agents, 2007, 30, 546-550.	1.1	9
388	Regional trends in \hat{l}^2 -lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001 \hat{a} \in 2004. Journal of Infection, 2007, 55, 111-118.	1.7	102
389	Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum \hat{l}^2 -lactamases. Clinical Microbiology and Infection, 2007, 13, 532-538.	2.8	11
390	CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy, 2006, 59, 165-174.	1.3	756
391	Common Region CR1 for Expression of Antibiotic Resistance Genes. Antimicrobial Agents and Chemotherapy, 2006, 50, 2544-2546.	1.4	42
392	In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. International Journal of Antimicrobial Agents, 2006, 28, 75-78.	1.1	40
393	Respiratory tract infections: at-risk patients, who are they?Implications for their management with levofloxacin. International Journal of Antimicrobial Agents, 2006, 28, S115-S127.	1.1	13
394	Evaluation of 4 swab transport systems for the recovery of ATCC and clinical strains with characterized resistance mechanisms. Diagnostic Microbiology and Infectious Disease, 2006, 56, 19-24.	0.8	25
395	Nosocomial and community-acquired meticillin-resistant Staphylococcus aureus infections in hospitalized patients (Spain, 1993–2003). Journal of Hospital Infection, 2006, 63, 465-471.	1.4	34
396	The CTX-M β-lactamase pandemic. Current Opinion in Microbiology, 2006, 9, 466-475.	2.3	982

#	Article	IF	CITATIONS
397	Genetic and phenotypic differences among Enterococcus faecalis clones from intestinal colonisation and invasive disease. Clinical Microbiology and Infection, 2006, 12, 1193-1198.	2.8	24
398	EUCAST Technical Note on tigecycline. Clinical Microbiology and Infection, 2006, 12, 1147-1149.	2.8	72
399	In117, an Unusual In0-Like Class 1 Integron Containing CR1 and bla CTX-M-2 and Associated with a Tn 21 -Like Element. Antimicrobial Agents and Chemotherapy, 2006, 50, 799-802.	1.4	34
400	Dissemination and Persistence of bla CTX-M-9 Are Linked to Class 1 Integrons Containing CR1 Associated with Defective Transposon Derivatives from Tn 402 Located in Early Antibiotic Resistance Plasmids of IncHI2, IncP1-α, and IncFI Groups. Antimicrobial Agents and Chemotherapy, 2006, 50, 2741-2750.	1.4	108
401	Antibiotic Coresistance in Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline. Antimicrobial Agents and Chemotherapy, 2006, 50, 2695-2699.	1.4	145
402	Combinations of PBPs and MurM protein variants in early and contemporary high-level penicillin-resistant Streptococcus pneumoniae isolates in Spain. Journal of Antimicrobial Chemotherapy, 2006, 57, 983-986.	1.3	18
403	Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-Producing Enterobacteriaceae Strains Containing the aac(6 $\hat{a} \in 2$)-lb-cr Gene, Which Encodes an Aminoglycoside- and Fluoroquinolone-Modifying Enzyme. Antimicrobial Agents and Chemotherapy, 2006, 50, 3220-3221.	1.4	95
404	Multilocus Sequence Typing Scheme for Enterococcus faecalis Reveals Hospital-Adapted Genetic Complexes in a Background of High Rates of Recombination. Journal of Clinical Microbiology, 2006, 44, 2220-2228.	1.8	321
405	Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. Journal of Antimicrobial Chemotherapy, 2006, 59, 301-304.	1.3	42
406	Role of the microbiology laboratory in infectious disease surveillance, alert and response. Clinical Microbiology and Infection, 2005, 11, 3-8.	2.8	76
407	Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection, 2005, 11, 690-703.	2.8	134
408	Tratamiento antimicrobiano frente a la colonizaci \tilde{A}^3 n pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis qu \tilde{A} stica. Archivos De Bronconeumologia, 2005, 41, 1-25.	0.4	55
409	Population Structure, Antimicrobial Resistance, and Mutation Frequencies of Streptococcus pneumoniae Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2005, 43, 2207-2214.	1.8	56
410	Scarce Evidence of Yogurt Lactic Acid Bacteria in Human Feces after Daily Yogurt Consumption by Healthy Volunteers. Applied and Environmental Microbiology, 2005, 71, 547-549.	1.4	75
411	Integron Content of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Strains over 12 Years in a Single Hospital in Madrid, Spain. Antimicrobial Agents and Chemotherapy, 2005, 49, 1823-1829.	1.4	174
412	Increased Mutation Frequencies in Escherichia coli Isolates Harboring Extended-Spectrum β-Lactamases. Antimicrobial Agents and Chemotherapy, 2005, 49, 4754-4756.	1.4	37
413	Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. Journal of Antimicrobial Chemotherapy, 2005, 56, 220-223.	1.3	39
414	Telithromycin activity is reduced by efflux in Streptococcus pyogenes. Journal of Antimicrobial Chemotherapy, 2005, 55, 489-495.	1.3	23

#	Article	IF	Citations
415	Nationwide Study of Escherichia coli and Klebsiella pneumoniae Producing Extended-Spectrum \hat{l}^2 -Lactamases in Spain. Antimicrobial Agents and Chemotherapy, 2005, 49, 2122-2125.	1.4	139
416	CTX-M-10 Linked to a Phage-Related Element Is Widely Disseminated among Enterobacteriaceae in a Spanish Hospital. Antimicrobial Agents and Chemotherapy, 2005, 49, 1567-1571.	1.4	70
417	Population Structure of Enterococcus faecium Causing Bacteremia in a Spanish University Hospital: Setting the Scene for a Future Increase in Vancomycin Resistance?. Antimicrobial Agents and Chemotherapy, 2005, 49, 2693-2700.	1.4	79
418	Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips. Journal of Clinical Microbiology, 2005, 43, 4480-4485.	1.8	50
419	Multi-resistant Enterobacteriaceae in Hospital Practice. , 2004, , 205-243.		O
420	Laboratory Detection of Haemophilus influenzae with Decreased Susceptibility to Nalidixic Acid, Ciprofloxacin, Levofloxacin, and Moxifloxacin Due to gyrA and parC Mutations. Journal of Clinical Microbiology, 2004, 42, 1185-1191.	1.8	35
421	High Genetic Diversity among Stenotrophomonas maltophilia Strains Despite Their Originating at a Single Hospital. Journal of Clinical Microbiology, 2004, 42, 693-699.	1.8	103
422	Dynamics of Long-Term Colonization of Respiratory Tract by Haemophilus influenzae in Cystic Fibrosis Patients Shows a Marked Increase in Hypermutable Strains. Journal of Clinical Microbiology, 2004, 42, 1450-1459.	1.8	91
423	Emergence of CTX-M \hat{I}^2 -lactamase-producing Enterobacteriaceae in Portugal: report of an Escherichia coli isolate harbouring blaCTX-M-14. Clinical Microbiology and Infection, 2004, 10, 755-757.	2.8	17
424	Dramatic Increase in Prevalence of Fecal Carriage of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae during Nonoutbreak Situations in Spain. Journal of Clinical Microbiology, 2004, 42, 4769-4775.	1.8	290
425	Resistance Trends in Moraxella catarrhalis (PROTEKT Years 1–3 [1999–2002]). Journal of Chemotherapy, 2004, 16, 63-70.	0.7	5
426	Antimicrobial susceptibility profile of molecular typed cystic fibrosisStenotrophomonas maltophiliaisolates and differences with noncystic fibrosis isolates. Pediatric Pulmonology, 2003, 35, 99-107.	1.0	41
427	Antimicrobial Resistance in Recent Fecal Enterococci from Healthy Volunteers and Food Handlers in Spain: Genes and Phenotypes. Microbial Drug Resistance, 2003, 9, 47-60.	0.9	76
428	Quality Control for \hat{l}^2 -Lactam Susceptibility Testing with a Well-Defined Collection of Enterobacteriaceae and Pseudomonas aeruginosa Strains in Spain. Journal of Clinical Microbiology, 2003, 41, 1912-1918.	1.8	21
429	In Vitro Activities of Garenoxacin (BMS-284756) against Haemophilus influenzae Isolates with Different Fluoroquinolone Susceptibilities. Antimicrobial Agents and Chemotherapy, 2003, 47, 3539-3541.	1.4	13
430	Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance. Journal of Antimicrobial Chemotherapy, 2003, 51, 147-151.	1.3	16
431	Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases. Antimicrobial Agents and Chemotherapy, 2003, 47, 2692-2695.	1.4	17
432	Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. Journal of Antimicrobial Chemotherapy, 2003, 52, 50-55.	1.3	30

#	Article	IF	CITATIONS
433	Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. Journal of Antimicrobial Chemotherapy, 2003, 52, 944-952.	1.3	107
434	Multi-resistant Gram-negative bacilli: from epidemics to endemics. Current Opinion in Infectious Diseases, 2003, 16, 315-325.	1.3	106
435	Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales espaA±oles (Proyecto GEIH-BLEE 2000). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2003, 21, 77-82.	0.3	53
436	Genes Encoding TEM-4, SHV-2, and CTX-M-10 Extended-Spectrum \hat{I}^2 -Lactamases Are Carried by Multiple Klebsiella pneumoniae Clones in a Single Hospital (Madrid, 1989 to 2000). Antimicrobial Agents and Chemotherapy, 2002, 46, 500-510.	1.4	178
437	Epidemiology of Extended-Spectrum Â-Lactamase-Producing Enterobacter Isolates in a Spanish Hospital during a 12-Year Period. Journal of Clinical Microbiology, 2002, 40, 1237-1243.	1.8	119
438	Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. Journal of Antimicrobial Chemotherapy, 2002, 49, 289-300.	1.3	95
439	Risk factors associated with ampicillin resistance in patients with bacteraemia caused by Enterococcus faecium. Journal of Antimicrobial Chemotherapy, 2002, 50, 1003-1009.	1.3	28
440	Antimicrobial resistance amongst isolates of <i>Streptococcus pyogenes</i> and <i>Staphylococcus aureus</i> in the PROTEKT antimicrobial surveillance programme during 1999-2000. Journal of Antimicrobial Chemotherapy, 2002, 50, 9-24.	1.3	79
441	High occurrence of esp among ampicillin-resistant and vancomycin-susceptible Enterococcus faecium clones from hospitalized patients. Journal of Antimicrobial Chemotherapy, 2002, 50, 1035-1038.	1.3	56
442	Role of partner's infection in reinfection after Helicobacter pylori eradication. European Journal of Gastroenterology and Hepatology, 2002, 14, 865-871.	0.8	41
443	Allodemics. Lancet Infectious Diseases, The, 2002, 2, 591-592.	4.6	36
444	Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates. International Journal of Antimicrobial Agents, 2001, 17, 371-376.	1.1	18
445	Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. Diabetes Research and Clinical Practice, 2001, 52, 1-9.	1.1	24
446	Validation of the VITEK2 and the advance expert system with a collection of enterobacteriaceae harboring extended spectrum or inhibitor resistant \hat{l}^2 -lactamases. Diagnostic Microbiology and Infectious Disease, 2001, 41, 65-70.	0.8	17
447	Variations in the Prevalence of Strains Expressing an Extendedâ€Spectrum βâ€Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific Region. Clinical Infectious Diseases, 2001, 32, S94-S103.	2.9	352
448	Prevalence of extended-spectrum \hat{l}^2 -lactamases in group-1 \hat{l}^2 -lactamase-producing isolates. Clinical Microbiology and Infection, 2001, 7, 278-282.	2.8	6
449	Evaluation of the OSIRIS video reader system for disk diffusion susceptibility test reading. Clinical Microbiology and Infection, 2001, 7, 352-357.	2.8	17
450	Antimicrobial Susceptibilities of Unique Stenotrophomonas maltophilia Clinical Strains. Antimicrobial Agents and Chemotherapy, 2001, 45, 1581-1584.	1.4	74

#	Article	IF	Citations
451	In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2001, 45, 2427-2431.	1.4	40
452	Antimicrobial resistance in Helicobacter pylori. Reviews in Medical Microbiology, 2001, 12, 47-61.	0.4	7
453	Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing \hat{l}^2 -Lactamase (CTX-M-10) Isolated in Spain. Antimicrobial Agents and Chemotherapy, 2001, 45, 616-620.	1.4	106
454	Nontuberculous Mycobacteria in Patients with Cystic Fibrosis. Clinical Infectious Diseases, 2001, 32, 1298-1303.	2.9	83
455	Persistence and variability of Stenotrophomonas maltophilia in Cystic Fibrosis Patients, Madrid, 1991-1998. Emerging Infectious Diseases, 2001, 7, 113-122.	2.0	51
456	Concordance Between Noninvasive Tests in Detecting Helicobacter pylori and Potential Use of Serology for Monitoring Eradication in Gastric Ulcer. Journal of Clinical Gastroenterology, 2000, 31, 137-141.	1.1	11
457	Applications of Flow Cytometry to Clinical Microbiology. Clinical Microbiology Reviews, 2000, 13, 167-195.	5.7	207
458	Applications of Flow Cytometry to Clinical Microbiology. Clinical Microbiology Reviews, 2000, 13, 167-195.	5.7	143
459	Outbreak of a Multiresistant Klebsiella pneumoniae Strain in an Intensive Care Unit: Antibiotic Use as Risk Factor for Colonization and Infection. Clinical Infectious Diseases, 2000, 30, 55-60.	2.9	160
460	High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection. Science, 2000, 288, 1251-1253.	6.0	1,322
461	Evaluation of the Wider System, a New Computer-Assisted Image-Processing Device for Bacterial Identification and Susceptibility Testing. Journal of Clinical Microbiology, 2000, 38, 1339-1346.	1.8	48
462	Ampicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of $\langle i \rangle$ Escherichia coli $\langle i \rangle$ Isolates with Different \hat{l}^2 -Lactam Resistance Phenotypes. Antimicrobial Agents and Chemotherapy, 1999, 43, 862-867.	1.4	27
463	MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care unit patient surveillance cultures. Clinical Microbiology and Infection, 1999, 5, 554-559.	2.8	7
464	Comparative In Vitro Activity of Quinolones Against Stenotrophomonas maltophilia. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 908-911.	1.3	27
465	Mutations in 23S rRNA in <i>Helicobacter pylori</i> Conferring Resistance to Erythromycin Do Not Always Confer Resistance to Clarithromycin. Antimicrobial Agents and Chemotherapy, 1999, 43, 374-376.	1.4	31
466	Failure to detect Helicobacter pylori in vaginal secretions. Clinical Microbiology and Infection, 1998, 4, 412-413.	2.8	3
467	Aerosolized vancomycin for the treatment of methicillin-resistantStaphylococcus aureus infection in cystic fibrosis., 1998, 26, 287-289.		51
468	Helicobacter pylori infection and insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice, 1998, 39, 143-146.	1.1	59

#	Article	IF	CITATIONS
469	Association of Helicobacter pylori Infection With Cardiovascular and Cerebrovascular Disease in Diabetic Patients. Diabetes Care, 1998, 21, 1129-1132.	4.3	56
470	Antimicrobial Susceptibility Profiles of Oropharyngeal Viridans Group Streptococci Isolates from Cystic Fibrosis and Non-Cystic Fibrosis Patients. Microbial Drug Resistance, 1998, 4, 123-128.	0.9	4
471	Helicobacter pylori Infection Is Markedly Increased in Patients With Autoimmune Atrophic Thyroiditis. Journal of Clinical Gastroenterology, 1998, 26, 259-263.	1.1	113
472	Soft Salt-Mannitol Agar–Cloxacillin Test: a Highly Specific Bedside Screening Test for Detection of Colonization with Methicillin-Resistant <i>Staphylococcus aureus</i> Microbiology, 1998, 36, 986-989.	1.8	23
473	ABO blood groups, rhesus factor and Helicobacter pylori. Revista Espanola De Enfermedades Digestivas, 1998, 90, 263-8.	0.1	3
474	Relation between Histologic Subtypes and Location of Gastric Cancer and <i>Helicobacter pylori</i> Scandinavian Journal of Gastroenterology, 1997, 32, 303-307.	0.6	41
475	Helicobacter pylori Infection with Parietal Cell Antibodies in Children and Adolescents with Insulin Dependent Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 1997, 10, 511-6.	0.4	18
476	Current patterns and evolution of antibiotic resistance among bacterial pathogens involved in acute otitis media. Clinical Microbiology and Infection, 1997, 3, 3S26-3S33.	2.8	3
477	Lung colonization with Enterobacteriaceae producing extended-spectrum \hat{l}^2 -lactamases in cystic fibrosis patients. , 1997, 24, 213-217.		9
478	Bacteriologic diagnosis of respiratory tract infection. Clinical Microbiology and Infection, 1996, 1, $2S10-2S15$.	2.8	8
479	Î ² -Lactam stability in frozen microdilution PASCO MIC panels using strains with known resistance mechanisms as biosensors. Diagnostic Microbiology and Infectious Disease, 1996, 26, 53-61.	0.8	18
480	Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrobial Agents and Chemotherapy, 1996, 40, 1741-1744.	1.4	127
481	In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Journal of Antimicrobial Chemotherapy, 1996, 37, 1-18.	1.3	40
482	Helicobacter pylori infection in a healthy population in Spain. European Journal of Gastroenterology and Hepatology, 1996, 8, 1165-1168.	0.8	40
483	Long-Term Persistence of Ciprofloxacin-Resistant Haemophilus influenzae in Patients with Cystic Fibrosis. Journal of Infectious Diseases, 1996, 174, 1345-1347.	1.9	37
484	Characterization of a Nosocomial Outbreak Involving an Epidemic Plasmid Encoding for TEM-27 in Salmonella enterica Subspecies enterica Serotype Othmarschen. Journal of Infectious Diseases, 1996, 174, 1015-1020.	1.9	52
485	Verification of Decreased Basal and Stimulated Serum Pepsinogen-I Levels Is a Useful Non-Invasive Method for Determining the Success of Eradication Therapy forHelicobacter pylori. Scandinavian Journal of Gastroenterology, 1996, 31, 103-110.	0.6	18
486	New extended-spectrum TEM-type beta-lactamase from Salmonella enterica subsp. enterica isolated in a nosocomial outbreak. Antimicrobial Agents and Chemotherapy, 1995, 39, 458-461.	1.4	72

#	Article	lF	CITATIONS
487	High seroprevalence of Helicobacter pylori infection in coronary heart disease. Lancet, The, 1995, 346, 310.	6.3	43
488	Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy, 1993, 37, 2059-2063.	1.4	168
489	Galenical formulations of amoxicillin/clavulanate and eradication of Helicobacter pylori in peptic ulcer patients. European Journal of Gastroenterology and Hepatology, 1993, 5, 283-286.	0.8	14
490	The emergence of highly fluoroquinolone-resistant Eschericha coli in community-acqntred urinary tract infections. Journal of Antimicrobial Chemotherapy, 1992, 29, 349-350.	1.3	92
491	Aminoglycoside-modifying enzymes in clinical isolates harboring extended-spectrum beta-lactamases. Antimicrobial Agents and Chemotherapy, 1992, 36, 2536-2538.	1.4	18
492	The E-Test as an epidemiologic tool. Diagnostic Microbiology and Infectious Disease, 1992, 15, 483-487.	0.8	20
493	Abstract form for the Irish Journal of Medical Science v workshop on gastroduodenal pathology and Helicobacter pylori July 5th — 7th 1992 — Dublin, Ireland. Irish Journal of Medical Science, 1992, 161, 1-31.	0.8	1
494	The Incidence and Beta-lactam Resistance of <i>Proteus vulgaris </i> Ion Hospital Infections: the Last Decade. Journal of Chemotherapy, 1991, 3, 283-288.	0.7	2
495	Beta-lactamase producingHaemophilus influenzae as causative agent of a liver abscess. European Journal of Clinical Microbiology and Infectious Diseases, 1989, 8, 748-749.	1.3	3
496	Levels of insulin in the brains of rats modified by chronic administration of amphetamine, haloperidol and sulpiride. Neuropharmacology, 1988, 27, 1141-1144.	2.0	3
497	Amphetamine and chlorpromazine modify cerebral insulin levels in rats. Life Sciences, 1988, 42, 21-25.	2.0	6
498	In vitro and in vivo antiaggregant effects of magnesium halogenates. Thrombosis and Haemostasis, 1987, 58, 957-9.	1.8	2
499	CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Frontiers in Microbiology, 0, 13, .	1.5	20